FDA Announces Joint Meeting of Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee

Summary

The US Food and Drug Administration (FDA) has scheduled a joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss various topics related to endocrinologic and metabolic drugs.